Previous 10 |
home / stock / esalf / esalf news
TOKYO, Feb 21, 2019 - (JCN Newswire) - AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant], "HUMIRA"), a fully human anti-TNF-alpha monoclonal ant...
TOKYO, Feb 13, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency (EMA) for its in-house discovered antiepileptic drug (AED) Fycompa (perampanel) seeking approval for use in pediatric patients with epilepsy. This appli...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2018 Q3 earnings Read more ...
Eisai ( OTCPK:ESALF ): 9M GAAP EPS of ¥139.46. More news on: Eisai Co., Ltd., Eisai Co., Ltd. ADR, Earnings news and commentary, Healthcare stocks news, Read more ...
At the Sleep Research Society's Conference: Advances in Sleep and Circadian Science Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant TOKYO, Feb 4, 2019 - (JCN Newswire) - Eisai Co., Ltd. and ...
To what should be absolutely no human being's surprise, another amyloid-antibody trial has failed. Roche ([[RHHBY]]) announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. The company is still going on with...
As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation TOKYO, Jan 30, 2019 - (JCN Newswire) - Eisai Co., Ltd. has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa (...
Highest Ranked Japanese Company TOKYO, Jan 22, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Ei...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...